Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological & Psychiatric Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NMDAR2B/GRIN2B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | GRIN2B Promise-ORF / Lentivirus Particles. Full-length human GRIN2B for stable cell lines. Co-transduction with GRIN1 available for functional tetramer assembly. Essential for preserving complex ion channel conformation. | View GRIN2B Products |
| Antigen | GRIN2B Extracellular Domain (ATD/ECD) Recombinant Fragments / Mutant Protein. High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. HEK293 expressed (native glycosylation). Theoretical MW confirmed. | View GRIN2B Products |
| Benchmark Ab | Anti-GRIN2B Benchmark Antibody. Recombinant positive control for assay standardization, expression validation, and target engagement studies. | View GRIN2B Products |
| Validator | GRIN2B siRNA Set. For knockdown verification and assay specificity control. | View GRIN2B Products |
| Related Target A | GRIN1 (NR1). Obligatory heteromeric partner required for functional NMDAR channel assembly and surface trafficking. | View GRIN1 Products |
| Related Target B | GRIN2A (NR2A). Developmentally regulated subfamily switch; essential selectivity counter-screen to rule off-target subunit effects. | View GRIN2A Products |
Critical Assay Challenges and Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Ion Channel | Lentivirus Premade Particles for native membrane expression in HEK293/CHO cells. Required for Calcium Flux assays. |
| Subunit Selectivity (vs GRIN2A/2C/2D) | Homolog panel sequence-verified constructs available for rigorous patch-clamp counter-screening. |
| Lack of Reliable Controls | Sequence-verified Recombinant benchmark antibodies and validated siRNA included for assay integrity. |
Live NMDAR2B/GRIN2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NMDAR2B/GRIN2B therapeutics is intensifying, with major players shifting focus from traditional non-selective channel blockers to highly specific Negative Allosteric Modulators (NAMs). As first-generation non-selective therapies reach the clinic with associated psychotomimetic side effects, the next wave of R&D is targeting subunit-selective small molecules and peptides to safely address Treatment-Resistant Depression (TRD), Alzheimer's Disease, and neuropathic pain without the dissociative liabilities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (NAM) | Janssen, Relmada Therapeutics | Major Depressive Disorder | Cell-based Calcium Flux (Need Lentivirus for Stable Cell Line) |
| Small Molecule (PAM) | Cerevel Therapeutics | Schizophrenia (Cognitive) | Electrophysiology (Need specific GRIN1/GRIN2B co-expression) |
| Peptide Modulators | Various Biotechs | Stroke / Neuroprotection | Receptor Binding (Need High Purity Extracellular Domains) |
Key Mutations and Clinical Significance
Several naturally occurring mutations in GRIN2B have been identified with clinical implications. The missense variant rs1057519553 (c.1936C>T p.Arg646Cys) is associated with Developmental and Epileptic Encephalopathy 27 (DEE27) and classified as uncertain significance. Another variant, rs201094029 (p.Leu581Pro), is also under investigation. Additionally, a mutation found in a schizophrenia patient (p.Ile262Thr) highlights the potential role of GRIN2B in psychiatric disorders (UniProt Q13224). Understanding these genetic variants is critical for developing personalized therapeutics and validating disease models.